Sign in
Active, not recruitingPhase 2/3

Low-dose Atropine for Myopia Control in Children

Key facts

Who runs it
University Eye Hospital, Freiburg
Where
Germany16 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 2/3
People taking part
302 people enrolled
Started
19 Oct 2021
Expected to end
Nov 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Atropine eye drops, 0.01%
  • Atropine eye drops, 0.02%
  • Placebo (NaCl 0.9%) eye drops
Record updated
6 March 2025

Who can take part

Age
8 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Male or female patients aged 8 to 12 years (up to the day before the 13th birthday)
  • Myopia of -1 D to -6 D with reported or documented annual progression ≥ 0.5 D of myopia
  • Written informed consent obtained from patient (if applicable) and parents or legal guardians according to international guidelines and local laws
  • Ability to understand the nature of the trial and the trial related procedures and to comply with them

Who cannot take part

  • Previous use of any kind of contact lenses
  • Previous use of atropine eye drops
  • Participation in any other interventional clinical trial within the last 30 days before the start of this trial
  • History of amblyopia
  • Any acquired or developmental organic eye disease
  • Any known systemic metabolic disease or chromosomal anomaly
  • Epilepsy
  • Known hypersensitivity to the active substances or any of the excipients
  • Caution and pediatric counselling shall be assured if any of the following conditions are present according to the Summary of Product Characteristics (SmPC): Cardiac insufficiency, arrhythmia, coronary stenosis, hyperthyroidism, stomach or bowel stenosis, bowel paralysis, megacolon, muscle weakness, lung edema, hypersensitivity to atropine, spastic paralysis
  • Asian or African origin
  • Abnormal binocularity
  • Strabismus
  • Astigmatism >1.5 D
  • Anisometropia >1.5 D
  • Corrected visual acuity in any eye <0.63
  • Premature birth
  • Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registries and diagnostic trials is allowed
  • Contraindications according to the Summary of Product Characteristics (SmPC): Increased intraocular pressure (primary forms of glaucoma or narrow angle glaucoma), chronic rhinitis sicca
  • Parents or children with poor understanding of the German language
  • Person who is in a relationship of dependence/employment with the sponsor or the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Myopia (nearsightedness) is the most common eye disorder. Only second to age, it is the main risk factor for major degenerative eye diseases such as glaucoma, macular degeneration or retinal detachment. Their risk increases with the degree of myopia. Hence, prevention of myopia and slowing its progression is of high relevance. Almost all clinical studies, including two large randomised clinical trials (RCT) were performed in Asia with Asian study participants. The results indicate that atropine eye drops can attenuate myopic progression in children, even in low concentrations thus minimizing unwanted side effects. However, the cumulative evidence is yet not strong enough to recommend their unrestricted use, especially in a Non-Asian population. We therefore intend to set up an adequately powered RCT comparing atropine 0.02% eye drops with placebo to validate previous findings and to test whether this therapeutic concept holds its promise in a European population.

The 2 groups in the trial

  • Arm A, Interventional groupTreatment being tested

    Treatment period 1: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 3: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months

    Treatment: Atropine eye drops, 0.02% and Placebo (NaCl 0.9%) eye drops

  • Arm B, Control groupTreatment being tested

    Treatment period 1: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months Treatment period 3: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months

    Treatment: Atropine eye drops, 0.01% and Placebo (NaCl 0.9%) eye drops

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Low-dose Atropine for Myopia Control in Children, a Prospective, Double-blind, Placebo-controlled, Multicentric, Randomized Clinical Trial
Publications
Record updated
6 March 2025